News and analysis on disease research and diagnostics.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
Assessing T cell fraction alongside tumor thickness was superior to other histopathological variables for accurate progression-free survival prediction.
